Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Byoung Chul Cho et al.|The Lancet|2019Cited by 3.3k
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03Satoshi Teramukai, Masanori Fukushima, Toshiyuki Kitano et al.|European Journal of Cancer|2009Cited by 342